Encrypted login | home

Program Information

Clinical Guidelines for Determining When An Adaptive Replan May Be Warranted for Head and Neck Patients

K Brock

K Brock*, C Lee , S Samuels , M Robbe , C Lockhart , M Schipper , M Matuszak , A Eisbruch , University of Michigan, Ann Arbor, MI


TU-AB-303-5 (Tuesday, July 14, 2015) 7:30 AM - 9:30 AM Room: 303

Purpose: Tools are now available to perform daily dose assessment in radiotherapy, however, guidance is lacking as to when to replan to limit increase in normal tissue dose. This work performs statistical analysis to provide guidance for when adaptive replanning may be necessary for head/neck (HN) patients.

Methods: Planning CT and daily kVCBCT images for 50 HN patients treated with VMAT were retrospectively evaluated. Twelve of 50 patients were replanned due to anatomical changes noted over their RT course. Daily dose assessment was performed to calculate the variation between the planned and delivered dose for the 38 patients not replanned and the patients replanned using their delivered plan. In addition, for the replanned patients, the dose that would have been delivered if the plan was not modified was also quantified. Deviations in dose were analyzed before and after replanning, the daily variations in patients who were not replanned assessed, and the predictive power of the deviation after 1, 5, and 15 fractions determined.

Results: Dose deviations were significantly reduced following replanning, compared to if the original plan would have been delivered for the entire course. Early deviations were significantly correlated with total deviations (p<0.01). Using the criteria that a 10% increase in the final delivered dose indicates a replan may be needed earlier in the treatment course, the following guidelines can be made with a 90% specificity after the first 5 fractions: deviations of 7% in the mean dose to the inferior constrictors and 5% in the mean dose to the parotid glands and submandibular glands. No significant dose deviations were observed in any patients for the CTV_70Gy (max deviation 4%).

Conclusions: A 5-7% increase in mean dose to normal tissues within the first 5 fractions strongly correlate to an overall deviatios in the delivered dose for HN patients.

Funding Support, Disclosures, and Conflict of Interest: This work is funded in part by NIH 2P01CA059827-16

Contact Email: